Iovance Biotherapeutics (IOVA) News Today → Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad) Free IOVA Stock Alerts $11.86 +0.54 (+4.77%) (As of 04/23/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineThese Biotech Stocks Could Soar 120% and 295%, According to Wall Streetfool.com - April 21 at 5:08 AMIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)globenewswire.com - April 19 at 5:15 PMZacks Research Comments on Iovance Biotherapeutics, Inc.'s FY2024 Earnings (NASDAQ:IOVA)americanbankingnews.com - April 18 at 2:02 AMIovance Biotherapeutics, Inc. Expected to Earn FY2024 Earnings of ($1.57) Per Share (NASDAQ:IOVA)marketbeat.com - April 17 at 5:39 PMIs Iovance Biotherapeutics Stock a Buy Now?fool.com - April 17 at 9:45 AMIovance Biotherapeutics Enters Oversold Territory (IOVA)nasdaq.com - April 17 at 2:32 AMFirst Week of May 31st Options Trading For Iovance Biotherapeutics (IOVA)nasdaq.com - April 17 at 2:32 AMMarket Sentiment Around Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)finance.yahoo.com - April 17 at 2:32 AMThe Top 5 Analysts Ranked by Marketbeat and Stocks They Covermarketbeat.com - April 9 at 7:01 AMThe Top 5 Analysts Ranked by Marketbeat and Stocks They Cover (IOVA)marketbeat.com - April 9 at 7:00 AMIovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Resultsseekingalpha.com - April 9 at 6:05 AMIovance Biotherapeutics (NASDAQ:IOVA) Shares Down 3.7% marketbeat.com - April 8 at 2:30 PMBetter Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeuticsfool.com - April 5 at 5:03 AMVanguard Group Inc. Purchases 1,748,082 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)marketbeat.com - April 5 at 4:07 AMObsidian lands $160M Series C —but IPO still in the cardsbizjournals.com - April 3 at 5:05 PMBuy Rating for Werewolf Therapeutics: Innovation and Financial Stability Signal Promising Future in Immunotherapymarkets.businessinsider.com - April 3 at 7:03 AMSG Americas Securities LLC Sells 187,664 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)marketbeat.com - April 3 at 4:18 AMIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of "Buy" from Analystsmarketbeat.com - April 2 at 4:22 AMAnalysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Atara Biotherapeutics (ATRA)markets.businessinsider.com - April 1 at 2:43 AMCity Council wants the gene therapy industry to hire Philadelphians without a college degreemsn.com - March 29 at 12:47 PMIovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?finance.yahoo.com - March 29 at 12:47 PMIovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 6%marketbeat.com - March 28 at 8:23 PM2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Streetfool.com - March 26 at 4:11 AMIovance Biotherapeutics: Initial Amtagvi Launch In Focusseekingalpha.com - March 26 at 1:26 AMIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)globenewswire.com - March 22 at 5:30 PMIovance Biotherapeutics (NASDAQ:IOVA) Trading Down 1.7%marketbeat.com - March 22 at 1:44 PMQ1 2024 EPS Estimates for Iovance Biotherapeutics, Inc. Lowered by Zacks Research (NASDAQ:IOVA)marketbeat.com - March 22 at 7:35 AMIovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 4.8%marketbeat.com - March 21 at 4:53 PMIovance Biotherapeutics, Inc. to Post FY2026 Earnings of ($1.03) Per Share, Zacks Research Forecasts (NASDAQ:IOVA)marketbeat.com - March 21 at 8:36 AMIovance Biotherapeutics (NASDAQ:IOVA) Trading Up 2.2%marketbeat.com - March 20 at 3:12 PMIovance Biotherapeutics (NASDAQ:IOVA) shareholders are still up 122% over 1 year despite pulling back 7.1% in the past weekfinance.yahoo.com - March 19 at 5:36 PMIovance Biotherapeutics (NASDAQ:IOVA) Trading Down 0.6%marketbeat.com - March 19 at 2:03 PM7 Biotech Stocks Ready to Ride the Sector's Resurgenceinvestorplace.com - March 18 at 8:01 PMPiper Sandler Increases Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $19.00marketbeat.com - March 18 at 6:00 PMIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Short Interest Updatemarketbeat.com - March 18 at 5:14 PMIovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 3.2%marketbeat.com - March 18 at 2:46 PMHudson Bay Capital Management LP Purchases 155,200 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)marketbeat.com - March 17 at 5:11 AMAnalysts Are Bullish on Top Healthcare Stocks: Silk Road Medical (SILK), Arcellx Inc (ACLX)markets.businessinsider.com - March 15 at 3:16 AMPiper Sandler Maintains Overweight Rating for Iovance Biotherapeutics: Here's What You Need To Knowmarkets.businessinsider.com - March 14 at 5:12 PMBanque Pictet & Cie SA Purchases 99,636 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)marketbeat.com - March 13 at 8:25 AMKennedy Capital Management LLC Has $1.57 Million Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)marketbeat.com - March 10 at 6:54 AMIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of "Buy" by Brokeragesmarketbeat.com - March 8 at 3:41 AMTruist Securities Maintains Buy Rating for Iovance Biotherapeutics: Here's What You Need To Knowmarkets.businessinsider.com - March 7 at 12:53 PMIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Holdings Raised by Seven Eight Capital LPmarketbeat.com - March 7 at 8:39 AM1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17?fool.com - March 7 at 7:52 AMPositive Outlook for Iovance Biotherapeutics: Buy Rating Justified by Clinical Advancements and Strong Financialsmarkets.businessinsider.com - March 6 at 4:51 PMIovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analystfool.com - March 6 at 4:42 AMIovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Up After Analyst Upgrademarketbeat.com - March 4 at 10:31 AMFDA Lifts Clinical Hold On Iovance Biotherapeutics' IOV-LUN-202 Study In Non-Small Cell Lung Cancermarkets.businessinsider.com - March 4 at 8:49 AMIovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancerglobenewswire.com - March 4 at 6:30 AM Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (Ad)Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver. Learn More Now IOVA Media Mentions By Week IOVA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IOVA News Sentiment▼0.120.44▲Average Medical News Sentiment IOVA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IOVA Articles This Week▼86▲IOVA Articles Average Week Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ImmunityBio News Today SpringWorks Therapeutics News Today Apogee Therapeutics News Today Arcellx News Today Immunocore News Today CG Oncology News Today Denali Therapeutics News Today Vericel News Today Immunovant News Today Beam Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IOVA) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
